Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054815 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
A Phase 2 study, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT06054815: Completed Phase 2 study, sponsored by NeuroBo Pharmaceuticals.
NCT06054815 is a Phase 2 study that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 109 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06054815, a Phase 2 study, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
Primary Outcome
To explore the efficacy (change from baseline in alanine transaminase \[ALT\]) of DA-1241 in subjects at risk of NASH or subjects with non-alcoholic fatty liver disease (NAFLD) after administration of oral DA-1241 at varying doses of placebo and in combination with sitagliptin.
Interventions
- DRUG Sitagliptin
- DRUG DA-1241
- DRUG Sitagliptin Placebo
- DRUG DA-1241 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
What the finished NCT06054815 record still lists
NCT06054815 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 4 interventions - of which Sitagliptin is the first listed.
NCT06054815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06054815 about?
NCT06054815 is a clinical study titled "Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH". A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
What is the current status of trial NCT06054815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2023-09-14. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT06054815?
The interventions under investigation include: Sitagliptin (DRUG), DA-1241 (DRUG), Sitagliptin Placebo (DRUG), DA-1241 Placebo (DRUG).
Who is sponsoring clinical trial NCT06054815?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06054815's enrollment target sits among peer trials
109 640th of 2000 higher than 1,361 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI